| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-09-04 23:17:36 UTC |
|---|
| Updated at | 2022-09-04 23:17:37 UTC |
|---|
| NP-MRD ID | NP0203762 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | (2s,5r,6r)-6-{[(2r)-1-hydroxy-2-{[hydroxy(2-hydroxy-4,5-dihydroimidazol-1-yl)methylidene]amino}-2-phenylethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
|---|
| Description | Azlocillin, also known as baye 6905 or securopen, belongs to the class of organic compounds known as peptides. Peptides are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another. Azlocillin is a drug which is used for the treatment of infections caused by pseudomonas aeruginosa, escherichia coli, and haemophilus influenzae. (2s,5r,6r)-6-{[(2r)-1-hydroxy-2-{[hydroxy(2-hydroxy-4,5-dihydroimidazol-1-yl)methylidene]amino}-2-phenylethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid is found in Apis cerana. (2s,5r,6r)-6-{[(2r)-1-hydroxy-2-{[hydroxy(2-hydroxy-4,5-dihydroimidazol-1-yl)methylidene]amino}-2-phenylethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid was first documented in 1982 (PMID: 6212725). Azlocillin is an extremely weak basic (essentially neutral) compound (based on its pKa) (PMID: 10090000) (PMID: 11036013) (PMID: 19292999) (PMID: 20363776) (PMID: 21219695) (PMID: 21360610). |
|---|
| Structure | [H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1 InChI=1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12-,13+,16-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | ChEBI | | Azlocilina | ChEBI | | Azlocilline | ChEBI | | Azlocillinum | ChEBI | | (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-{[(2R)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate | Generator | | Azlocillin sodium salt | HMDB | | Azlocillin, sodium | HMDB | | Baye 6905 | HMDB | | Bayer brand OF azlocillin | HMDB | | Securopen | HMDB | | Azlocillin sodium | HMDB | | Azlin | HMDB | | Sodium azlocillin | HMDB | | Sodium, azlocillin | HMDB | | Azlocillin bayer brand | HMDB | | Bay e 6905 | HMDB | | Bay-e 6905 | HMDB |
|
|---|
| Chemical Formula | C20H23N5O6S |
|---|
| Average Mass | 461.4920 Da |
|---|
| Monoisotopic Mass | 461.13690 Da |
|---|
| IUPAC Name | (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetamido]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
|---|
| Traditional Name | azlocillin |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | [H][C@](NC(=O)N1CCNC1=O)(C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@]12[H])C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12-,13+,16-/m1/s1 |
|---|
| InChI Key | JTWOMNBEOCYFNV-NFFDBFGFSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, H2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as peptides. Peptides are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | Peptides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Alpha peptide
- Penicillin
- N-acyl-alpha amino acid or derivatives
- N-carbamoyl-alpha-amino acid or derivatives
- Alpha-amino acid amide
- N-substituted-alpha-amino acid
- Alpha-amino acid or derivatives
- Phenylacetamide
- Penam
- Imidazolidinone
- Monocyclic benzene moiety
- Benzenoid
- Imidazolidine
- Beta-lactam
- Tertiary carboxylic acid amide
- Thiazolidine
- Azetidine
- Urea
- Carbonic acid derivative
- Carboxamide group
- Secondary carboxylic acid amide
- Lactam
- Organoheterocyclic compound
- Azacycle
- Hemithioaminal
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Dialkylthioether
- Thioether
- Organic nitrogen compound
- Organic oxide
- Carbonyl group
- Hydrocarbon derivative
- Organonitrogen compound
- Organooxygen compound
- Organopnictogen compound
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Wright AJ: The penicillins. Mayo Clin Proc. 1999 Mar;74(3):290-307. doi: 10.4065/74.3.290. [PubMed:10090000 ]
- Franceschini N, Caravelli B, Docquier JD, Galleni M, Frere JM, Amicosante G, Rossolini GM: Purification and biochemical characterization of the VIM-1 metallo-beta-lactamase. Antimicrob Agents Chemother. 2000 Nov;44(11):3003-7. doi: 10.1128/AAC.44.11.3003-3007.2000. [PubMed:11036013 ]
- Marina M, Ivanova M, Kantardjiev T: Antimicrobial susceptibility of anaerobic bacteria in Bulgaria. Anaerobe. 2009 Aug;15(4):127-32. doi: 10.1016/j.anaerobe.2009.03.002. Epub 2009 Mar 16. [PubMed:19292999 ]
- Radomski N, Cambau E, Moulin L, Haenn S, Moilleron R, Lucas FS: Comparison of culture methods for isolation of nontuberculous mycobacteria from surface waters. Appl Environ Microbiol. 2010 Jun;76(11):3514-20. doi: 10.1128/AEM.02659-09. Epub 2010 Apr 2. [PubMed:20363776 ]
- Peres RL, Palaci M, Loureiro RB, Dietze R, Johnson JL, Maciel EL: Reduction of contamination of mycobacterial growth indicator tubes using increased PANTA concentration. Int J Tuberc Lung Dis. 2011 Feb;15(2):281-3, i. [PubMed:21219695 ]
- Asandei A, Apetrei A, Luchian T: Uni-molecular detection and quantification of selected beta-lactam antibiotics with a hybrid alpha-hemolysin protein pore. J Mol Recognit. 2011 Mar-Apr;24(2):199-207. doi: 10.1002/jmr.1038. [PubMed:21360610 ]
- Subramanyam B, Sivaramakrishnan GN, Dusthackeer A, Nagamiah S, Kumar V: Phage lysin as a substitute for antibiotics to detect Mycobacterium tuberculosis from sputum samples with the BACTEC MGIT 960 system. Clin Microbiol Infect. 2012 May;18(5):497-501. doi: 10.1111/j.1469-0691.2011.03601.x. Epub 2011 Aug 29. [PubMed:21883661 ]
- Roy C, Segura C, Fuster C, Tirado M, Foz A: [Antibacterial spectrum of mezlocillin and azlocillin, two new antibiotics of the ureidopenicillin group (author's transl)]. Med Clin (Barc). 1982 May 1;78(9):363-71. [PubMed:6212725 ]
- Godard J, Aubertin J, Borderon JC, Dureux JB, Motin J: [Monotherapy of Pseudomonas aeruginosa septicemia with azlocillin]. Presse Med. 1984 Mar 29;13(13):819-21. [PubMed:6231603 ]
- Fass RJ: Comparative in vitro activities of azlocillin-cefotaxime and azlocillin-tobramycin combinations against blood and multi-drug resistant bacterial isolates. Antimicrob Agents Chemother. 1982 Jul;22(1):167-9. doi: 10.1128/AAC.22.1.167. [PubMed:6289737 ]
- Petit JC, Richard G, Burghoffer B, Daguet GL: [Synergistic activity between ticarcillin, azlocillin, cefsulodin, ceftazidime and tobramycin or amikacin against Pseudomonas aeruginosa (author's transl)]. Pathol Biol (Paris). 1982 Jun;30(6):426-31. [PubMed:6810286 ]
- LOTUS database [Link]
|
|---|